BioCentury on BioBusiness,
Product Discovery & Development
Banking heavily on APACHE III
Monday, March 29, 1993
Banking heavily on APACHE III
By Karen Bernstein
The physician who devised the modified APACHE III method of prospectively defining patients who will benefit from sepsis drugs hopes that the system will become the "common language" of sepsis trials, permitting comparison of future trials and allowing clinicians to consider the efficacy of cocktails of drugs.
William Knaus, director of the ICU research unit at the George Washington Medical Center in Washington, D.C., led a team of researchers that devised an APACHE III prognostic system specific to sepsis patients. The team applied the entry criteria for Synergen Inc.'s Phase III Antril IL-1ra trial to a database of 60,000 critically ill patients and came up with 1,200 patients who met the criteria, Knaus told BioCentury.
Importance to SYGN
"We found out what each factor was and built a model of patient characteristics at entry that influence the outcome," he said. Thus, in contrast to other companies' entry criteria for new Phase III trials, which have been based on retrospective analyses of patients in earlier trials, Knaus said his model was independently reached ahead of time based on a separate patient group.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]